Considerations for the Clinical Impact of Next-Generation Imaging in Prostate Cancer

Ashley E. Ross, MD, PhD, Executive Medical Director of the Mary Crowley Cancer Research Center in Dallas, discusses the current and potential impact of PSMA PET imaging on the identification and treatment of localized prostate cancer. He notes how PET PSMA and fluciclovine imaging can increase the accuracy of detecting clinically significant localized disease. Dr. Ross further discusses how PET imaging assists in risk stratification of candidates for treatment of HSPC, nmCRPC using salvage local therapy, metastasis-directed therapy, or intensification of systemic therapy. He also discusses how PET imaging can help identify candidates for cure with local treatments.

Prostate cancer,Diagnostic imaging,nmCRPC,HSPC,PET Imaging,PSMA,Fluciclovine,PSMA PET,Fluciclovine PET,Localized Prostate Cancer,